Interaction between GSTM1-null and CYP2D6-deficient alleles in the pathogenesis of Parkinson's disease

European Journal of Neurology

Volumn 11, Issue 4, 2004, Pages 247-251

  Santt, O ^a,b   Baranova, H ^b   Albuisson, E ^c   Bignon, Y J ^b   Lucotte, G ^a,d  

^a Center of Molecular Neurogenetics   (France)

^b CENTRE JEAN PERRIN   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d Centre de Neurogenetique Moleculaire   (France)

Author keywords

Cytochrome P450 2D6 gene; Glutathione S transferase M1 gene; Interaction study; Null and deficient alleles; Parkinson's disease

Indexed keywords

CYTOCHROME P450 2D6; GLUTATHIONE TRANSFERASE;

ADULT; AGED; ALLELE; ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BLOTTING, SOUTHERN; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 1842845157     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2003.00756.x     Document Type: Article

References (22)

1. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR (1992). Mutant debrosiquine hydroxylation genes in Parkinson's disease. Lancet 339:1017-1018.
2. Brandman O, Vaughan J, Holmans P, Marsden CD, Wood NW (1997). Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 350:1136-1139.
3. Brockmöller J, Kerb R, Drakoulis N, Staffeldt B, Roots I (1994). Glutathione S-transferase M1 and its variants A and B as host factor's of bladder cancer susceptibility: a case/control study. Cancer Res 54:4104-4111.
4. Coleman T, Ellis SW, Martin IJ, Lennard MS, Tucker GT (1996). MTP is N-demethylated by cytochrome P4502D6, 1A2 and 3A4; implications for susceptibility to Parkinson's disease. J Pharmacol Exp Ther 277:685-690.
5. Dupret JM, Longuemaux S, Lucotte G (1999). Acetylator genotype for N-Acetyltransferase 2 and Parkinson's disease. Ann Neurol 46:433-434.
6. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA (1991). Detection of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 48:943-950.
7. Gautreau C, Rahuel C, Cartron JP, Lucotte G (1993). Comparison of two methods of high molecular weight DNA isolation from human leucocytes. Anal Biochem 134:320-324.
8. Gérard N, Panserat S, Lucotte G (2002). Roles of gender, age at onset and environmental risk in the frequency of CYP2D6-deficient alleles in patients with Parkinson's disease. Eur Neurol 48:114-115.
9. Gilham DE, Cairno W, Paine MJ et al. (1997). Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human fœtal and adult brain by in situ hybridization. Xenobiotica 27:111-125.
10. Gough AC, Miles JS, Spurr NK et al. (1990). Identification of the primary gene defect at the cytochrome P450 CYP2D6 locus. Nature 347:773-776.
11. Kurth MC and Kurth JH (1993). Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am J Med Genet 48:166-168.
12. Langston JW, Ballard P, Tetrud JW, Irwin I (1983). Chronic parkisonism in humans due to a product of meperidine-analog synthesis. Science 219:970-980.
13. Le Couteur DG, Leighton PW, Mc Cann SJ, Pond SM (1997). Association of a polymorphism in the dopamine-transporter gene with Parkinson's disease. Movment Disorders 12:760-763.
14. Lucotte G, Turpin JC, Gérard N, Panserat S, Krishnamoorthy R (1996). Mutation frequencies of the cytochrome CYP2D6 gene in Parkinson's disease patients and families. Am J Med Genet 67:361-365.
15. McCann SJ, Pond SM, James KM, Le Couteur DG (1997). The association between polymorphisms in the cytochrome P-4502D6 and Parkinson's disease: a case control study and meta-analysis. J Neurol Sci 153:50-53.
16. Mercier G, Turpin JC, Lucotte G (1999). Variable number of tandem repeat dopamine transporter gene polymorphism and Parkinson's disease: no association found. J Neurol 246:45-47.
17. Saxena R, Shaw GL, Relling MV et al. (1994). Identification of a new variant CYP2D6 single base pair deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 3:923-926.
18. Seidegard J, Pero RW, Markowitz MM et al. (1999). Isozyme of glutathione transferase (class μ) as a marker for susceptibility to lung cancer: a follow-up study. Carcinogenesis 11:33-36.
19. Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M (2001). Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11:237-245.
20. Smith CAD, Gough AC, Leigh PN et al. (1992). Association between CYP2D6-debroxine hydroxylase polymorphism and susceptibility to Parkinson's disease. Lancet 339:1375-1377.
21. Stroombergen M, Waring RH (1999). Determination of glutathionine S-transferase μ and θ polymorphisms in neurological disease. Human Experimental Toxicology 18:141-145.
22. Tanner, CM, Langston JW (1990). Do environmental toxins cause Parkinson's disease? A critical review. Neurology 40(s3):17-30.